Zobrazeno 1 - 1
of 1
pro vyhledávání: '"Pimienta Neira, Fernando José"'
Publikováno v:
Rahman F, Kwan GF, Benjamin EJ. Global epidemiology of atrial fibrillation. Nat Rev Cardiol. 2016 Jul 14;13(8):501.
Rosselli D, Rodríguez AJ, García AA, Rueda JD. Prevalencia de fibrilación auricular en un hospital universitario colombiano. Rev Colomb Cardiol; 20(6): 283-385.
Pinto DA, Sánchez-Vallejo CA, López A, Vergara EP,Sáenz OS, González F, et al. Descripción de los pacientes con fibrilación auricular no valvular que ingresan al servicio de urgencias. Rev Colomb Cardiol. 2016;23(4):270-276.
Narayan SM, Cain ME, Smith JM. Atrial Fibrillation, Lancet. 1997 Sept 27;350 (9082): 943-50
Dorantes M. Something of history. Rev Cubana Cardiol Cir Cardiovasc 2010; 16(4):518-22.
Fuster V, Ryden LE, Cannom DS, Crikins HJ, Curtis AB, Ellenbogen KA, et al. ACC/AHA/ESC 2006 Guidelines for the Management of Patients with Atrial Fibrillation: a report of the American College of Cardiology/American Heart Association Circulation 2006; 114:257-354.
Schotten Ulrich, VerheuleSander, Kirchhof P, Goette A.Pathophysiological mechanisms of atrial fibrillation: a translational appraisal. Physiol. Rev. 2011;91 (1):265–325.
Wadke Rahul. Atrial brillation. Dis Mon. 2013;59 (3):67–73.
Gillis AM, Verma A, Talajic M, Nattel S, Dorian P. Canadian Cardiovascular Society atrial brillation guidelines 2010: rate and rhythm management. Can J Cardiol 2011; 27:47–59.
January CT, Wann LS, Alpert JS, Calkins H, Cleveland JC, Conti JB, et al. 2014 AHA/ACC/HRS Guideline for the Management of Patients with Atrial Fibrillation: Executive Summary: A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the Heart Rhythm Society. J Am Coll Cardiol. 2014; 64(21): 2246–80.
Go AS. Hylek EM, Phillips KA, Chang Y, Henault LE, Selby JV, Singer DE. Prevalence of diagnosed atrial fibrillation in adults: national implications for rhythm management and stroke prevention: the AnTicoagulation and Risk Factors in Atrial Fibrillation (ATRIA) study. JAMA. 2001 May 9;285(18):2370-5.
Lip GY, Bawden L, Hodson R, Rutland E, Snatchfold J, Beevers DG. Atrial fibrillation amongst the Indo-Asian general practice population. The West Birmingham Atrial Fibrillation Project. Int J Cardiol. 1998 Jul 1;65(2):187-92.
Chugh SS, Havmoeller R, Narayana K, Singh D, Rienstra m, Benjamin EJ, et al. Worldwide epidemiology of atrial fibrillation: A Global Burden of Disease 2010 Study. Circulation. 2014 Feb 25;129(8):837-47.
Lip GY. Niuewlaat R, Pisters R, Lane DA, Crijns HJ. Refining clinical risk stratification for predicting stroke and thromboembolism in atrial fibrillation using a novel risk factor-based approach: the euro heart survey on atrial fibrillation. Chest. 2010 Feb;137(2):263-72.
Page RL, Kerber RE, Russell JK, Trouton T, Walktare J, Gallik D, et al. Biphasic versus monophasic shock waveform for conversion of atrial fibrillation: the results of an international randomized, double-blind multicenter trial. J Am Coll Cardiol. 39, 1956–1963 (2002).
Martínez-Marcos FJ, García-Garmendia JL, Ortega-Carpio A, Fernández-Gómez JM, Santos JM, Camacho C. Comparison of intravenous flecainide, propafenone, and amiodarone for conversion of acute atrial fibrillation to sinus rhythm. Am J Cardiol 2000; 86:950-3.
Gage BF, Waterman AD, Shannon W, Boechler M, Rich MW, Radford MJ. Validation of clinical classification schemes for predicting stroke. JAMA. 2001 Jun 13;285(22):2864-70.
Guo Y, Apostolakis S, Blann AD, Wang H, Zhao X, Zhang Y, et al. Validation of contemporary stroke and bleeding risk stratification scores in non-anticoagulated Chinese patients with atrial fibrillation. Int J Cardiol. 2013 Sep 30;168(2):904-9.
Marini C, De Santis F, Sacco S, Russo T, Olivieri L, Totaro R, et al. Contribution of atrial fibrillation to incidence and outcome of ischemic stroke: results from a population-based study. Stroke. 2005 Jun;36(6):1115-9.
McManus DD, Hsu G, Sung SH, Saczynski JS, Smith DH, Magid DJ, et al. Atrial fibrillation and outcomes in heart failure with preserved versus reduced left ventricular ejection fraction. J Am Heart Assoc. 2013 Feb 1;2(1): e005694.
Katsanos AH, Mavridis D, Parissis J, Deftereos S, Frogoudaki A, Vrettou AR, et al. Novel oral anticoagulants for the secondary prevention of cerebral ischemia: a network meta-analysis. Ther Adv Neurol Disord. 2016 Sep;9(5):359-68.
Camm AJ. The RE-LY study: Randomized Evaluation of Long-term anticoagulant therapy: dabigatran vs. warfarin. Eur Heart J. 2009 Nov;30(21):2554-5.
Patel MR, Mahaffey KW, Garg J, Pan G, Singer DE, Hacke W, et al. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med. 2011;365(10):883–91. 10.1056.
Granger CB, Alexander JH, McMurray JJ, Lopes RD, Hylek EM, Hanna M, et al.: Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med. 2011; 365(11): 981–92.
Pisters R, Lane DA, Nieuwalaat R, deVos CB, Crijns HJ, Lip GY. A Novel User-Friendly Score (HAS-BLED) to Assess 1-Year Risk of Major Bleeding in Patients With Atrial Fibrillation. CHEST. 2010; 138 (5): 1093-1100.
Rapaport SI, Rao LV. The tissue factor pathway: how it has become a "prima ballerina". Thromb Haemost 1995; 74:7.
Mann KG, Brummel-Ziedins K, Orfeo T, Butenas S. Models of blood coagulation. Blood Cells Mol Dis 2006; 36:108.
Pérez-Gómez F. The new coagulation cascade and its possible influence on the delicate balance between thrombosis and hemorrhage. Rev Esp Cardiol. 2007 Dec;60(12):1217-9.
Laux V, Perzborn E, Heitmeier S, von Degenfeld G, Dittrich-Wengenroth E, Buchmüññer A, et al. Direct inhibitors of coagulation proteins-the end of the heparin and low-molecular-weight heparin era for anticoagulant therapy?. Thromb Haemost. 2009 Nov;102(5):892-9.
Wadhera RK, Russell CE; Piazza G. Cardiology patient page. Warfarin versus novel oral anticoagulants: how to choose? Circulation. 2014 Nov 25;130(22):e191-3.
Kawabata-Yoshihara, LA, Benseñor IM, Kawabata VS, Menezes PR, Scazufca M, Lotufo PA. Prevalence of electrocardiographic findings in elderly individuals: the São Paulo Aging & Health Study. Arq. Bras. Cardiol. 93, 602–607 (2009).
Repositorio EdocUR-U. Rosario
Universidad del Rosario
instacron:Universidad del Rosario
Rosselli D, Rodríguez AJ, García AA, Rueda JD. Prevalencia de fibrilación auricular en un hospital universitario colombiano. Rev Colomb Cardiol; 20(6): 283-385.
Pinto DA, Sánchez-Vallejo CA, López A, Vergara EP,Sáenz OS, González F, et al. Descripción de los pacientes con fibrilación auricular no valvular que ingresan al servicio de urgencias. Rev Colomb Cardiol. 2016;23(4):270-276.
Narayan SM, Cain ME, Smith JM. Atrial Fibrillation, Lancet. 1997 Sept 27;350 (9082): 943-50
Dorantes M. Something of history. Rev Cubana Cardiol Cir Cardiovasc 2010; 16(4):518-22.
Fuster V, Ryden LE, Cannom DS, Crikins HJ, Curtis AB, Ellenbogen KA, et al. ACC/AHA/ESC 2006 Guidelines for the Management of Patients with Atrial Fibrillation: a report of the American College of Cardiology/American Heart Association Circulation 2006; 114:257-354.
Schotten Ulrich, VerheuleSander, Kirchhof P, Goette A.Pathophysiological mechanisms of atrial fibrillation: a translational appraisal. Physiol. Rev. 2011;91 (1):265–325.
Wadke Rahul. Atrial brillation. Dis Mon. 2013;59 (3):67–73.
Gillis AM, Verma A, Talajic M, Nattel S, Dorian P. Canadian Cardiovascular Society atrial brillation guidelines 2010: rate and rhythm management. Can J Cardiol 2011; 27:47–59.
January CT, Wann LS, Alpert JS, Calkins H, Cleveland JC, Conti JB, et al. 2014 AHA/ACC/HRS Guideline for the Management of Patients with Atrial Fibrillation: Executive Summary: A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the Heart Rhythm Society. J Am Coll Cardiol. 2014; 64(21): 2246–80.
Go AS. Hylek EM, Phillips KA, Chang Y, Henault LE, Selby JV, Singer DE. Prevalence of diagnosed atrial fibrillation in adults: national implications for rhythm management and stroke prevention: the AnTicoagulation and Risk Factors in Atrial Fibrillation (ATRIA) study. JAMA. 2001 May 9;285(18):2370-5.
Lip GY, Bawden L, Hodson R, Rutland E, Snatchfold J, Beevers DG. Atrial fibrillation amongst the Indo-Asian general practice population. The West Birmingham Atrial Fibrillation Project. Int J Cardiol. 1998 Jul 1;65(2):187-92.
Chugh SS, Havmoeller R, Narayana K, Singh D, Rienstra m, Benjamin EJ, et al. Worldwide epidemiology of atrial fibrillation: A Global Burden of Disease 2010 Study. Circulation. 2014 Feb 25;129(8):837-47.
Lip GY. Niuewlaat R, Pisters R, Lane DA, Crijns HJ. Refining clinical risk stratification for predicting stroke and thromboembolism in atrial fibrillation using a novel risk factor-based approach: the euro heart survey on atrial fibrillation. Chest. 2010 Feb;137(2):263-72.
Page RL, Kerber RE, Russell JK, Trouton T, Walktare J, Gallik D, et al. Biphasic versus monophasic shock waveform for conversion of atrial fibrillation: the results of an international randomized, double-blind multicenter trial. J Am Coll Cardiol. 39, 1956–1963 (2002).
Martínez-Marcos FJ, García-Garmendia JL, Ortega-Carpio A, Fernández-Gómez JM, Santos JM, Camacho C. Comparison of intravenous flecainide, propafenone, and amiodarone for conversion of acute atrial fibrillation to sinus rhythm. Am J Cardiol 2000; 86:950-3.
Gage BF, Waterman AD, Shannon W, Boechler M, Rich MW, Radford MJ. Validation of clinical classification schemes for predicting stroke. JAMA. 2001 Jun 13;285(22):2864-70.
Guo Y, Apostolakis S, Blann AD, Wang H, Zhao X, Zhang Y, et al. Validation of contemporary stroke and bleeding risk stratification scores in non-anticoagulated Chinese patients with atrial fibrillation. Int J Cardiol. 2013 Sep 30;168(2):904-9.
Marini C, De Santis F, Sacco S, Russo T, Olivieri L, Totaro R, et al. Contribution of atrial fibrillation to incidence and outcome of ischemic stroke: results from a population-based study. Stroke. 2005 Jun;36(6):1115-9.
McManus DD, Hsu G, Sung SH, Saczynski JS, Smith DH, Magid DJ, et al. Atrial fibrillation and outcomes in heart failure with preserved versus reduced left ventricular ejection fraction. J Am Heart Assoc. 2013 Feb 1;2(1): e005694.
Katsanos AH, Mavridis D, Parissis J, Deftereos S, Frogoudaki A, Vrettou AR, et al. Novel oral anticoagulants for the secondary prevention of cerebral ischemia: a network meta-analysis. Ther Adv Neurol Disord. 2016 Sep;9(5):359-68.
Camm AJ. The RE-LY study: Randomized Evaluation of Long-term anticoagulant therapy: dabigatran vs. warfarin. Eur Heart J. 2009 Nov;30(21):2554-5.
Patel MR, Mahaffey KW, Garg J, Pan G, Singer DE, Hacke W, et al. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med. 2011;365(10):883–91. 10.1056.
Granger CB, Alexander JH, McMurray JJ, Lopes RD, Hylek EM, Hanna M, et al.: Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med. 2011; 365(11): 981–92.
Pisters R, Lane DA, Nieuwalaat R, deVos CB, Crijns HJ, Lip GY. A Novel User-Friendly Score (HAS-BLED) to Assess 1-Year Risk of Major Bleeding in Patients With Atrial Fibrillation. CHEST. 2010; 138 (5): 1093-1100.
Rapaport SI, Rao LV. The tissue factor pathway: how it has become a "prima ballerina". Thromb Haemost 1995; 74:7.
Mann KG, Brummel-Ziedins K, Orfeo T, Butenas S. Models of blood coagulation. Blood Cells Mol Dis 2006; 36:108.
Pérez-Gómez F. The new coagulation cascade and its possible influence on the delicate balance between thrombosis and hemorrhage. Rev Esp Cardiol. 2007 Dec;60(12):1217-9.
Laux V, Perzborn E, Heitmeier S, von Degenfeld G, Dittrich-Wengenroth E, Buchmüññer A, et al. Direct inhibitors of coagulation proteins-the end of the heparin and low-molecular-weight heparin era for anticoagulant therapy?. Thromb Haemost. 2009 Nov;102(5):892-9.
Wadhera RK, Russell CE; Piazza G. Cardiology patient page. Warfarin versus novel oral anticoagulants: how to choose? Circulation. 2014 Nov 25;130(22):e191-3.
Kawabata-Yoshihara, LA, Benseñor IM, Kawabata VS, Menezes PR, Scazufca M, Lotufo PA. Prevalence of electrocardiographic findings in elderly individuals: the São Paulo Aging & Health Study. Arq. Bras. Cardiol. 93, 602–607 (2009).
Repositorio EdocUR-U. Rosario
Universidad del Rosario
instacron:Universidad del Rosario
Introducción: En los últimos años se dispone de nuevos anticoagulantes orales para la fibrilación auricular. En Colombia su uso es más frecuente desde el año 2013. Se pretende caracterizar a los pacientes con fibrilación auricular no valvular
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::36432e2a037d1dc4e5a668388509fa27
http://repository.urosario.edu.co/handle/10336/12928
http://repository.urosario.edu.co/handle/10336/12928
